![Europe - European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure - RIS.WORLD Europe - European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure - RIS.WORLD](https://www.ris.world/wp-content/uploads/2019/03/EMA_1.jpg)
Europe - European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure - RIS.WORLD
![European Medicines Agency (EMA) launches pilot project on drug repurposing – EJP RD – European Joint Programme on Rare Diseases European Medicines Agency (EMA) launches pilot project on drug repurposing – EJP RD – European Joint Programme on Rare Diseases](https://www.ejprarediseases.org/wp-content/uploads/2021/10/EMApilotproject-e1635930571908-1200x600.png)
European Medicines Agency (EMA) launches pilot project on drug repurposing – EJP RD – European Joint Programme on Rare Diseases
![European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet | CDE Almería - Centro de Documentación Europea - Universidad de Almería European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet | CDE Almería - Centro de Documentación Europea - Universidad de Almería](https://www.cde.ual.es/wp-content/uploads/2021/11/Captura-6.png)
European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet | CDE Almería - Centro de Documentación Europea - Universidad de Almería
![The European Medicines Agency (EMA) is delivering a Product Management Service (PMS) and a Substance Management Service (SMS) to support regulatory activities in the European Union (EU) | Pharmya The European Medicines Agency (EMA) is delivering a Product Management Service (PMS) and a Substance Management Service (SMS) to support regulatory activities in the European Union (EU) | Pharmya](https://www.pharmya.com/wp-content/uploads/2023/02/Ema-logo.jpg)
The European Medicines Agency (EMA) is delivering a Product Management Service (PMS) and a Substance Management Service (SMS) to support regulatory activities in the European Union (EU) | Pharmya
![European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer - Action Kidney Cancer European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer - Action Kidney Cancer](https://actionkidneycancer.org/wp-content/uploads/2021/02/EMA.jpg)